Skip to content
Search

Latest Stories

UK patients first to participate in Moderna cancer vaccine trial

The trial aims to explore the therapy’s safety and its effectiveness against various solid tumours, including melanoma and lung cancer

UK patients first to participate in Moderna cancer vaccine trial

In a new development in the realm of cancer treatment, the UK has embarked on a pioneering journey by incorporating cancer patients into an international trial of an experimental mRNA therapy, known as mRNA-4359.

This innovative approach, which is currently under evaluation at Imperial College Healthcare NHS Trust, is at the forefront of the phase 1/2 clinical trials sponsored by Moderna, a report in The Economic Times said.


The trial aims to explore the therapy's safety and its effectiveness against various solid tumours, including melanoma and lung cancer, as outlined on Imperial College's website.

The essence of this therapy lies in its use of messenger RNA (mRNA) to introduce the immune system to common tumour markers, thereby training it to recognise and destroy cancer cells that display these markers.

This could potentially lead to the eradication of cells that would otherwise inhibit the immune response.

The collaboration between Imperial College and the Moderna-UK Strategic Partnership represents a significant stride in the UK's efforts to bolster its capabilities in mRNA vaccine production and enhance its readiness for future health crises.

As part of a decade-long agreement with the UK government, Moderna has pledged to invest heavily in research and development, including conducting various clinical trials within the country.

The study's initial phase is dedicated to assessing the therapy's safety and how well patients tolerate it, both as a standalone treatment and in combination with pembrolizumab, an immune checkpoint inhibitor.

The researchers are particularly interested in whether this combination can actively shrink tumours in patients with certain lung and skin cancers.

An 81-year-old man from Surrey, who was diagnosed with a form of malignant melanoma resistant to treatment in late October, had the distinction of being the first UK patient to receive mRNA-4359.

The government's collaboration with various pharmaceutical firms aims to push the boundaries of mRNA-based cancer immunotherapies, with several candidates currently undergoing early-stage clinical evaluations to determine their safety, feasibility, and initial efficacy.

The trial, an open-label, non-randomized Phase 1/2 study, involves all participants receiving identical treatment, with both clinicians and patients fully informed about the therapy being used. This approach fosters greater cooperation and understanding.

Cancer vaccines like mRNA-4359 are at the forefront of immunotherapy, designed to enhance the effectiveness of traditional treatments. These vaccines are divided into personalised therapies, utilising genetic material from a patient's tumours, and pre-designed therapies targeting specific cancer types.

The Mobilise trial is a groundbreaking effort by Imperial College London and Imperial College Healthcare NHS Trust, conducted at the NIHR Imperial Clinical Research Facility at Hammersmith Hospital.

Although the therapy is still in the preliminary stages of testing, there is optimism that it could emerge as a viable treatment for cancers that are notoriously difficult to manage, assuming its safety and effectiveness are confirmed.

Dr Kyle Holen of Moderna shared with The Telegraph their enthusiasm for the promising early results of the therapy, expressing hope for the ushering in of a new era in cancer treatment.

Similarly, Dr David Pinato and Dr Nichola Awosika from Imperial College London highlighted the innovative nature of mRNA-based cancer immunotherapies like mRNA-4359, which could offer less toxic and more targeted treatment options by harnessing the power of the patient's immune system against cancer.

The involvement of patients in the Mobilise trial has been lauded as crucial to the advancement of these novel treatments.

Professor Peter Johnson NHS national clinical director for cancer and Victoria Atkins, Secretary of State for Health, and Social Care, have both praised the cutting-edge work being done in the field and the transformative potential of cancer vaccines to save lives and revolutionise cancer therapy.

More For You

World Curry Festival 2025

The discovery coincides with Bradford’s City of Culture celebrations

World Curry Festival

Bradford’s first curry house traced back to 1942 ahead of World Curry Festival

Highlights:

  • Research for the World Curry Festival uncovered evidence of a curry house in Bradford in 1942.
  • Cafe Nasim, later called The Bengal Restaurant, is thought to be the city’s first.
  • The discovery coincides with Bradford’s City of Culture celebrations.
  • Festival events will include theatre, lectures, and a street food market.

Historic discovery in Bradford’s food heritage

Bradford’s claim as the curry capital of Britain has gained new historical depth. Organisers of the World Curry Festival have uncovered evidence that the city’s first curry house opened in 1942.

Documents revealed that Cafe Nasim, later renamed The Bengal Restaurant, once stood on the site of the current Kashmir Restaurant on Morley Street. Researcher David Pendleton identified an advert for the cafe in the Yorkshire Observer dated December 1942, describing it as “Bradford’s First Indian Restaurant”.

Keep ReadingShow less
​Dilemmas of dating in a digital world

We are living faster than ever before

AMG

​Dilemmas of dating in a digital world

Shiveena Haque

Finding romance today feels like trying to align stars in a night sky that refuses to stay still

When was the last time you stumbled into a conversation that made your heart skip? Or exchanged a sweet beginning to a love story - organically, without the buffer of screens, swipes, or curated profiles? In 2025, those moments feel rarer, swallowed up by the quickening pace of life.

Keep ReadingShow less
sugary drinks and ice cream

Researchers from the UK and US analysed data from American households between 2004 and 2019

iStock

Global warming may drive higher consumption of sugary drinks and ice cream, study warns

Highlights:

  • Hotter days linked to greater intake of sugary drinks and frozen desserts
  • Lower-income households most affected, research finds
  • Climate change could worsen health risks linked to sugar consumption
  • Study based on 15 years of US household food purchasing data

Sugary consumption rising with heat

People are more likely to consume sugary drinks and ice cream on warmer days, particularly in lower-income households, according to new research. The study warns that climate change could intensify this trend, adding to health risks as global temperatures continue to rise.

Sugar consumption is a major contributor to obesity, diabetes, and cardiovascular disease, and has surged worldwide in recent decades. The findings, published in Nature Climate Change, suggest that rising heat could be nudging more people towards high-sugar products such as soda, juice and ice cream.

Keep ReadingShow less
Camellia Panjabi's cookbook elevates
vegetables from sides to stars

Camellia Panjabi (Photo: Ursula Sierek)

Camellia Panjabi's cookbook elevates vegetables from sides to stars

RESTAURATEUR and writer Camellia Panjabi puts the spotlight on vegetables in her new book, as she said they were never given the status of a “hero” in the way fish, chicken or prawns are.

Panjabi’s Vegetables: The Indian Way features more than 120 recipes, with notes on nutrition, Ayurvedic insights and cooking methods that support digestion.

Keep ReadingShow less
Spotting the signs of dementia

Priya Mulji with her father

Spotting the signs of dementia

How noticing the changes in my father taught me the importance of early action, patience, and love

I don’t understand people who don’t talk or see their parents often. Unless they have done something to ruin your lives or you had a traumatic childhood, there is no reason you shouldn’t be checking in with them at least every few days if you don’t live with them.

Keep ReadingShow less